CTOs on the Move

BIOWEST THERAPEUTICS

www.migenix.com

 
BIOWEST THERAPEUTICS Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.migenix.com
  • 1727 Broadway W
    Vancouver, BC CAN V6J 4W6
  • Phone: 604.221.9666

Executives

Name Title Contact Details

Similar Companies

NantKwest

NantKwest is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel`s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

Segetis

Segetis, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anjarium Biosciences

Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.

Agenus

Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.